METHODS FOR TREATING HUNTINGTON'S DISEASE

(19)

(11)

EP 3 645 121 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	18.06.2025 Bulletin 2025/25

(45)	Mention of the grant of the patent:
	14.05.2025 Bulletin 2025/20

(21)	Application number: 18822625.2

(22)	Date of filing: 27.06.2018

(51)

International Patent Classification (IPC):

A61P 25/28^(2006.01)
C07D 239/70^(2006.01)
A61K 31/444^(2006.01)
A61K 31/551^(2006.01)
C07D 487/04^(2006.01)

A61K 31/517^(2006.01)
C07D 403/14^(2006.01)
A61K 31/519^(2006.01)
C07D 471/04^(2006.01)
C07D 519/00^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 31/517; A61P 25/28; A61K 31/444; A61K 31/519; A61K 31/551

(86)	International application number:
	PCT/US2018/039794

(87)	International publication number:
	WO 2019/005993 (03.01.2019 Gazette 2019/01)

(54)	METHODS FOR TREATING HUNTINGTON'S DISEASE VERFAHREN ZUR BEHANDLUNG VON MORBUS HUNTINGTON MÉTHODES DE TRAITEMENT DE LA MALADIE DE HUNTINGTON

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

28.06.2017 US 201762525838 P

(43)	Date of publication of application:
	06.05.2020 Bulletin 2020/19

(73)	Proprietor: PTC Therapeutics, Inc.
	Warren, NJ 07059 (US)

(72)	Inventors:
	BHATTACHARYYA, Anuradha Edison NJ 08820 (US) JANI, Minakshi, B. Iselin NJ 08830 (US)

(74)	Representative: Kolster Oy Ab
	Salmisaarenaukio 1 P.O. Box 204 00181 Helsinki 00181 Helsinki (FI)

(56)

References cited: :

EP-A1- 2 138 493
WO-A1-2017/081111
WO-A2-2012/104823
US-A1- 2015 005 289

WO-A1-2017/081111
WO-A1-2017/100726
US-A1- 2007 078 144
US-A1- 2017 000 794

DOUGLAS MACDONALD ET AL: "Quantification Assays for Total and Polyglutamine-Expanded Huntingtin Proteins", PLOS ONE, vol. 9, no. 5, 9 May 2014 (2014-05-09), pages 1 - 17, XP055390961, DOI: 10.1371/journal.pone.0096854

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).